This study demonstrates the plausibility of affibody molecules as HER3-targeting therapeutic agents for the inhibition of HER3-mediated tumor growth and corroborates previously obtained in vivo efficacy data pertaining to the structurally similar TAM-HER3 [21]. The gene discussed is ERBB3; the disease is neoplasm.